Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models

MLA

Nikki DeAngelis, et al. “Discovery and Pharmacological Characterization of Cetrelimab (JNJ-63723283), an Anti-Programmed Cell Death Protein-1 (PD-1) Antibody, in Human Cancer Models.” Cancer Chemotherapy and Pharmacology, vol. 89, no. 4, Sept. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c65f7a79203f381f3e394d4cf7ab1740&authtype=sso&custid=ns315887.

APA

Nikki DeAngelis, Catherine Ferrante, Gordon Powers, Jocelyn Sendecki, Bethany Mattson, Darlene Pizutti, Kathryn Packman, Weirong Wang, Kevin Trouba, Rupesh Nanjunda, John Wheeler, Ray Brittingham, Sheng-Jiun Wu, Jinquan Luo, Matthew V. Lorenzi, & Raluca I. Verona. (2021). Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models. Cancer Chemotherapy and Pharmacology, 89(4).

Chicago

Nikki DeAngelis, Catherine Ferrante, Gordon Powers, Jocelyn Sendecki, Bethany Mattson, Darlene Pizutti, Kathryn Packman, et al. 2021. “Discovery and Pharmacological Characterization of Cetrelimab (JNJ-63723283), an Anti-Programmed Cell Death Protein-1 (PD-1) Antibody, in Human Cancer Models.” Cancer Chemotherapy and Pharmacology 89 (4). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c65f7a79203f381f3e394d4cf7ab1740&authtype=sso&custid=ns315887.